Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Unmet needs and treatment patterns of advanced Parkinson’s Disease patients in the United States
Movement Disorders
Movement Disorders Posters (7:00 AM-5:00 PM)
177
Evaluate the burden of disease and treatment patterns among Advanced Parkinson’s Disease (APD) patients in the United States (US).
Parkinson’s Disease (PD) is a debilitating neurodegenerative disease with an expected exponential increase in prevalence. Recent efforts to quantify the burden of PD in the US have identified the need for further understanding the incremental burden for patients in higher disease severity.
The analytic sample consisted of US patients from the Adelphi Parkinson’s Disease Specific Programme™ (2017-2020). Patients were classified as early, intermediate, or advanced PD according to physician judgement. Demographics, clinical characteristics, healthcare resource utilization, treatment patterns and outcomes were compared between APD and non-APD patients (early or intermediate) using t-tests, chi-squared, and Fisher’s Exact tests as appropriate.
Of 1268 patients, 11.9% were classified as APD, of which majority (93.4%) were 65 years or older and having 8.1±4.4 years since diagnosis. APD patients experienced significantly greater (p<0.01) disease burden compared to non-APD as demonstrated by: (i) greater number of uncontrolled symptoms (10.6±5.9, 5.4±4.0), (ii) higher ADL dependence (90.1%, 39.5%), (iii) worse quality of life on Parkinson’s Disease Questionnaire-39 (35.8±16.2, 21.0±15.7), (iv) increased likelihood of PD-related hospitalizations within last 12 months (28.5%, 2.9%), (v) higher weekly hours of caregiver use (44.9±51.2, 5.1±16.4), and (vi) higher dissatisfaction with current treatment (11.6%, 3.4%). Majority (90.7%) of APD patients were on oral therapy and 14.9% received 1000 mg or higher Levodopa Equivalent Daily Dose. Among APD patients, 39.1% were considered by treating providers as candidates for device-aided therapy in the next 24 months. Top factors influencing treatment selection for oral and device-aided therapy included: maintaining quality of life (63.6%), reducing tremor (58.3%), rigidity (58.3%), and bradykinesia (49.0%). 

APD patients experience significant clinical, humanistic, and economic burden. Timely referral and management of APD patients might help alleviate unmet needs and reduce APD burden.
Authors/Disclosures
Irene Malaty, MD, FÂ鶹´«Ã½Ó³»­ (University of Florida)
PRESENTER 		Dr. Malaty has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. Dr. Malaty has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aevum. The institution of Dr. Malaty has received research support from Abbvie. The institution of Dr. Malaty has received research support from Revance. The institution of Dr. Malaty has received research support from Parkinson Foundation. The institution of Dr. Malaty has received research support from SAGE. The institution of Dr. Malaty has received research support from Emalex. The institution of Dr. Malaty has received research support from Acadia. Dr. Malaty has received publishing royalties from a publication relating to health care. Dr. Malaty has received personal compensation in the range of $500-$4,999 for serving as a Speaker & Center of Excellence Director with Parkinson Foundation. Dr. Malaty has a non-compensated relationship as a MAB member & Center of Excellence Directory with Tourette Association of America that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
No disclosure on file
Nabila Dahodwala, MD, FÂ鶹´«Ã½Ó³»­ (Parkinson's disease and Movement Disorders Center) Dr. Dahodwala has received personal compensation in the range of $0-$499 for serving as a Consultant for Genentech. Dr. Dahodwala has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mediflix. Dr. Dahodwala has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acadia. Dr. Dahodwala has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Post and Schell. Dr. Dahodwala has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for O'Brien & Ryan, LLP. Dr. Dahodwala has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for MotleyRice. The institution of Dr. Dahodwala has received research support from AbbVie. The institution of Dr. Dahodwala has received research support from Medtronic.
Ali Alobaidi, PharmD (AbbVie Inc) Dr. Alobaidi has received personal compensation for serving as an employee of AbbVie Inc. Dr. Alobaidi has received stock or an ownership interest from AbbVie Inc.
No disclosure on file
Yash Jalundhwala, PhD (AbbVie Inc) Dr. Jalundhwala has received personal compensation for serving as an employee of AbbVie . An immediate family member of Dr. Jalundhwala has received personal compensation for serving as an employee of AbbVie . Dr. Jalundhwala has received stock or an ownership interest from AbbVie.
Omar Ladhani Omar Ladhani has received personal compensation for serving as an employee of AbbVie. Omar Ladhani has received stock or an ownership interest from AbbVie.
Jack Wright (Adelphi Real World) Jack Wright has received personal compensation for serving as an employee of Adelphi Real World.
No disclosure on file
Ramon L. Rodriguez Cruz, MD, FÂ鶹´«Ã½Ó³»­ (Neurology One) The institution of Dr. Rodriguez Cruz has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie. The institution of Dr. Rodriguez Cruz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Supernus . The institution of Dr. Rodriguez Cruz has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurocrine. The institution of Dr. Rodriguez Cruz has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Boston Scientific. The institution of Dr. Rodriguez Cruz has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbott. The institution of Dr. Rodriguez Cruz has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Acorda. The institution of Dr. Rodriguez Cruz has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Teva. The institution of Dr. Rodriguez Cruz has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Kyoway Kirin. The institution of Dr. Rodriguez Cruz has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Abbvie. The institution of Dr. Rodriguez Cruz has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Amneal. The institution of Dr. Rodriguez Cruz has received research support from Cerevance. The institution of Dr. Rodriguez Cruz has received research support from Neuraly. The institution of Dr. Rodriguez Cruz has received research support from Amneal. The institution of Dr. Rodriguez Cruz has received research support from Teva. The institution of Dr. Rodriguez Cruz has received research support from Neurocrine. Dr. Rodriguez Cruz has received publishing royalties from a publication relating to health care.